Arena Pharmaceuticals is expected to book a wider loss than a year ago when it reports third-quarter earnings on Monday, November 3, 2014. Analysts are expecting a loss of 13 cents per share, down from a loss of eight cents per share a year ago.
The consensus estimate hasn't changed over the past month, but it's down from three months ago when it was a loss of 12 cents. Analysts are expecting a loss of 35 cents per share for the fiscal year. Revenue is expected to be $10.9 million for the quarter, 204% higher than the year-earlier total of $3.6 million. For the year, revenue is projected to come in at $43.6 million.
Arena Pharmaceuticals' profit in the last quarter followed losses in the three previous quarters.
Over the last four quarters, the company has seen its revenue grow by an average of more than threefold year-over-year. The more than threefold increase in the most recent quarter was the biggest rise.
Analysts are split on Arena Pharmaceuticals, but two of six analysts rate it hold.
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
